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ABSTRACT 
Objective: An efficient, high performance liquid chromatographic method has been developed and validated for the quantification of related 
substances in pioglitazone hydrochloride drug substance. 
Methods: This method includes the determination of three related substances in pioglitazone hydrochloride. The mobile phase A is 0.1% w/v 
triethylamine in water with pH 2.5 adjusted by dilute phosphoric acid. The mobile phase B is premixed and degassed mixtures of acetonitrile and 
methanol. The flow rate was 1 ml/min. The elution used was gradient mode. The HPLC column used for the analysis was symmetry C18 with a 
length of 250 mm, the internal diameter of 4.6 mm and particle size of 5.0 microns. 
Results: The developed method was found to be linear with the range of 0.006-250% with a coefficient of correlation 0.99. The precision study 
revealed that the percentage relative standard deviation was within the acceptable limit. The limit of detection and limit of quantitation of the 
impurities was less than 0.002%and 0.006% with respect to pioglitazone hydrochloride test concentration of 2000 µg/ml respectively. This method 
has been validated as per ICH guidelines Q2 (R1). 
Conclusion: A reliable, economical HPLC method was magnificently established for quantitative analysis of related substances of pioglitazone 
hydrochloride drug substance. 
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Pioglitazone is a prescription drug of the thiazolidinedione class 
with hypoglycemic action to treat diabetes. Pioglitazone is used to 
lower blood glucose levels in the treatment of diabetes mellitus type 
2 either alone or in combination with a sulfonylurea, metformin, 
or insulin. Pioglitazone has also been used to treat non-alcoholic 
steatohepatitis [1-2]. 
The related substances of pioglitazone hydrochloride have been 
developed and validated as per the selection of the synthetic route. 
Nowadays, the regulators were very much interested about the 
strategy of the control of impurities present in drug substances. 
They insist to have a regulation on impurities in each step of the 
synthetic drug process. Many studies were explained about the 
determination of pioglitazone was performed by HPLC [3-25, 27-31]. 
So as to determine the related substances of pioglitazone 
hydrochloride, the research work has been initiated. 
Several methods have been developed and validated only for the content 
of pioglitazone hydrochloride in drug substances or drug products and 
not for their related substances [3-25, 28-31]. This has been triggered us 
to perform the development activity for the determination of related 
substances in pioglitazone hydrochloride by HPLC and their structures 
were shown in fig. 1. As per the literature survey of the pioglitazone 
hydrochloride, no one has reported the most sensitive method for the 
determination of three impurities in pioglitazone hydrochloride drug 
substance by HPLC. These three impurities were determined at very 
low-level detection and quantitation in pioglitazone hydrochloride drug 
substance and this comprises the novelty of the article. 
MATERIALS AND METHODS 
Pioglitazone hydrochloride, PGR-II, PIO-II, N-oxide were gifted by 
Techno chemicals. The structure of related substances and pioglitazone 
hydrochloride has shown in fig. 1. Triethylamine, methanol, phosphoric 
acid and acetonitrile were bought from Fisher scientific. HPLC grade 
water was used, equipped with the Elga water purification system, 
Metrohm. Transferred 1 ml of triethylamine in 1000 ml water, adjusted 
the pH of the solution to 2.5 using dilute orthophosphoric acid, filtered 
and degassed [27-31]. This solution was named as mobile phase-A. 
Mixed 800 ml of acetonitrile and 200 ml of methanol, degassed and used 
as mobile phase-B. Water bath equipped with a controller (Amkette 
analytics, ANM alliance) was used for forced degradation studies. 
Photolytic studies were carried out in a photostability chamber 
(Thermolab photostability chamber, India). Thermal degradation works 




























Fig. 1: The structures of related substances and pioglitazone 
hydrochloride 
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Preparation of solutions 
The sample diluent was prepared by diluting 8.5 ml of concentrated 
hydrochloric acid in 1000 ml of water. Filtered and degassed for 
usage of analysis. The system suitability solution was prepared by 
exactly weighed and transferred about 10 mg each of PIO-II, PGR-II, 
N-oxide and pioglitazone standard in 100 ml volumetric flask. 
Dissolved and make upto the volume 100 ml with sample diluent. 
Further, 2 ml of this solution was diluted into a 100 ml volumetric 
flask and made up to the mark with sample diluent. So, the standard 
solution concentration was 100 µg/ml with respect to the test 
concentration of 2000 µg/ml pioglitazone hydrochloride. The sample 
solution was prepared by accurately weighed and transferred about 
100 mg of sample into 50 ml volumetric flask. Dissolved and make 
upto the volume 50 ml with sample diluent. The chromatograph of 
system suitability solution has been shown in fig. 2. 
 
 
Fig. 2: Chromatograms of system suitability solution 
 
Concluded method for validation purpose 
The HPLC column was used symmetry C18, 250 mm x 4.6 mm x 5.0 
µm. Transferred 1 ml of triethylamine in 1000 ml water, adjusted 
the pH of the solution to 2.5 using dilute orthophosphoric acid, 
filtered and degassed. This solution was named as mobile phase-A. 
Mixed 800 ml of acetonitrile and 200 ml of methanol, degassed and 
used as mobile phase-B. The gradient program was mentioned as 
min/%B composition; 0.00/20.0, 10.00/20.0, 35.00/40.0, 40.00/ 
80.0, 50/80.0, 51.00/20.0 and 60.00/20.0. The flow rate was 1 
ml/min. The wavelength of detection was 225 nm and the injection 
volume was 10 µl. The column compartment temperature was 
maintained at 45 °C. 
RESULTS 
Analytical method development 
Several methods have been developed by HPLC for the 
determination of pioglitazone in the bulk and formulated 
products [3-25, 28-31]. These previously published research 
articles were failed to explain about the determination of related 
substances in pioglitazone. This mainly leads us to do further 
development of the method with three impurities in pioglitazone 
by HPLC.  
The same column [3] has been used in the initial development. So, as 
to develop the sensitive method, the mobile phase, pH and gradient 
composition have been modified accordingly. The pH of the mobile 
phase was maintained in the acidic region, which was achieved by 
the addition of 1 ml of triethylamine in 1000 ml of water, adjusted 
the solution pH to 2.5 using dilute phosphoric acid. Generally, the 
mass compatible mobile phase needs to be selected, because if any 
impurities were detected at the level of above or below LOQ in the 
sample which needs to be confirmed using HPLC-MS study. But the 
mobile phase chosen for the study was not compatible with mass 
spectrometry (MS). So, this could be the limitation of the present 
research work. These three impurities have been eluted and 
separated well within the time of 40 min., but to ensure the 
consistency and specificity of the other impurities which was 
mentioned in the research article [27-31]; the gradient program has 
been slightly modified and extended up to 60 min. From this trial, 
the method was specific for all the impurities which have mentioned 
in the research article [27-31]. The results and comparisons of 
previously published articles were given in table 1. 
 
Table 1: Reported analytical HPLC methods for determination of pioglitazone (PIO) either alone or in combination with other drugs like 
metformin (MET), glimepiride (GLM), rosiglitazone (ROS) and gliclazide (GLC) in pharmaceutical dosage forms. 





3 In bulk and pharmaceutical 
formulations by HPLC and 
MEKC method 
0.01M KH2PO4 buffer (pH 
6.0):ACN (50:50, v/v) 
Symmetry C18 (250 
mm x 4.6 mmx 5 µm) 
225 1 - 
4 SIAM by RP-HPLC Phosphate buffer (pH 
4.0), ACN and methanol 
(55:30:15, v/v) 
Prontosil C8 (250 mm 
x 4.6 mm x 5 µm) 
254 1.5 - 
5 Study of stressed 
degradation behaviour in 
bulk and pharmaceutical 
formulation 
0.01M KH2PO4buffer (pH 
3.5)and methanol (55:45, 
v/v) 
Phenomenex Luna 
C18 (250 mm x 4.6 
mm x 5 µm) 
241 1.5 1.69 
6 Assay of tablets Ammonium formate 
buffer (pH 3): ACN 
(75:25, v/v) 
Nova-Pak C18 (150 
mm x 3.9 mm x 5 µm) 
225 1 - 
7 Purity test and assay of 
tablets 
Ammonium formate 
buffer (pH 4.1): ACN 
(45:55, v/v) 
Symmetry C18 (250 
mm x 4.6 mm x 5 µm) 
266 1 0.042 
8 SIAM ACN: (0.15, v/v) 
triethylamine (pH 4.6) 
(40:60, v/v) 
Hypersil C-8 (250 
mm x 4.6 mm x 5 µm) 
220 1.5 0.6 
9 Simultaneous determination 
with GLM 
0.01M triammonium 
citrate (pH 6.95):ACN: 
MeOH (45:35:20, v/v/v) 
Cosmosil C18 (150 
mm x 4.6 mm x 5 µm) 
228 1 - 
10 Simultaneous with MET ACN: KH2PO4 buffer (pH 
3) (50:50, v/v) 
Hypersil BDS C18 
(250 mm x 4.6 mm x 
5 µm) 
238 1 - 
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11 Simultaneous determination 
with GLM 
ACN: 0.02 M Ammonium 
acetate buffer (pH 4.5) 
(60:40, v/v) 
Inertsil ODS (250 mm 
x 4.6 mm x 5 µm) 
230 1 0.2 
12 Simultaneous determination 
with MET and GLM in tablet 
formulation 
MeOH: KH2PO4 buffer 
(pH 4.3) (75:25, v/v) 
Inertsil ODS-3 C18 
(250 mm x 4.6 mm x 
5 µm) 
258 1 - 
13 Simultaneous determination 
with saxagliptin in tablets 
ACN: 0.02 M KH2PO4 buffer 
(pH 7.0) (60:40, v/v) 
Inertsil C18 (150 mm 
x 4.6 mm x 5 µm) 
260 0.8 0.010 
14 Simultaneous determination 
with GLM 
ACN: 0.01 M KH2PO4 buffer 
(pH 6.2) (50:50, v/v) 
Eurosphere-100 C18 
(250 mm x 4.6 mm x 
5 µm) 
225 1.4 0.00049 
15 Simultaneous determination 
with GLM and ROS 
Dil. H3PO4 (pH 3.0): ACN 
(80:20, v/v) 
Nucleodur C-18 (250 
mm x 4.6 mm x 5 µm) 
215 0.8 0.19 
16 Estimation along with MET 
in tablets 
ACN: water: acetic acid 
(75:25:0.3, v/v/v), pH 5.5 
Hypersil ODS C18 
(250 mm x 4.6 mm x 
5 µm) 
230 0.5 0.009 
17 Simultaneous quantification 
with GLM and MET 
ACN: 0.01 M KH2PO4 
buffer-pH 5.0:THF 
(50:40:10, v/v/v) 
Inertsil ODS 3V (250 
mm x 4.6 mm x 5 µm) 
228 1.7 - 
18 Simultaneous estimation 
along with GLM 
ACN: KH2PO4 buffer 
(60:40, v/v) 
Inertsil ODS (150 mm 
x 4.6 mm x 5 µm)) 
225 1.5 0.12 
19 SIAM along with GLM Solution A: ACN 
Solution B: 0.02 M 
KH2PO4 buffer (pH: 3.2) 
Zorbax cyano (250 
mm x 4.6 mm x 5 µm) 
230 0.8 - 
20 Simultaneous determination 
with MET and GLC in 
multicomponent formulation 
MeOH: 0.02 M KH2PO4 
buffer (85:15, v/v) 
HiQSilC18 HS (250 
mm x 4.6 mm x 5 µm) 
227 1.2 0.1 
21 Simultaneous estimation 
with GLM 
Methanol: water (72:28, 
v/v) 
AgilentTC–C18 (250 
mm_4.6 mm,5 μm) 
230 1 0.760 
22 Simultaneous estimation 
with telmisartan 
ACN: ammonium 
dihydrogen phosphate (pH 
4.5; 0.02 M) (65:35, v/v) 
Phenomenex C8 (250 
mm_4.6 mm,5 μm) 
210 1 0.82 
23 Determination of along with 
MET and GLM 
ACN: phosphate buffer 
(pH 3) (65:35, v/v) 
PhenomenexRP-18 
(150 mm_4.6 mm,5 
μm) 
245 0.5 0.061 
24 Micellar liquid 
chromatographic analytical 
method for determination of 
atorvastatin calcium 
Tween-20: n-butanol: 
phosphate buffer, (pH 
4.2) (50:25:25,v/v/v) 
Luna C18 (250 
mm_4.6 mm,5 μm) 
 
322 1.5 - 
25 HPLC 0.01 M buffer, pH-
6.0:methanol (40:60, v/v) 
Symmetry–extend–
C18 (150 mm_4.6 
mm,5 μm) 
240 1.2 - 
27 SIAM for determination of 
impurities in PIO 
Sol-A: phosphate buffer 
pH 3.1 and Sol-B: 
acetonitrile 
Inertsil ODS-3V (150 
mm_4.6 mm,5 μm) 




HPLC Sol. A: 0.1% w/v 
triethylamine, pH 2.5 
Sol. B: ACN: MeOH 
(80:20) (v/v) 
Symmetry–C18 (250 
mm_4.6 mm,5 μm) 









ACN: Acetonitrile; MeOH: Methanol; LOQ: Limit of quantitation; LOD: Limit of detection 
 
Analytical method validation 
System suitability, system precision, method precision, detection 
limit, quantitation limit, linearity with regression and range, 
recovery, specificity/stress study, robustness and solution 
stability have been accomplished in the method validation study 
[26]. 
System suitability 
The system suitability solution was injected and calculated USP 
resolution for each peak. USP resolution was obtained above 5.0; the 
results were shown in table 2. (Limit: USP resolution should be more 
than 5.0 for each peak). The system precision results have been 
given in table 2. 
 
Table 2: System suitability results of PGR-II, PIO-II, N-oxide and pioglitazone 
Peak name RT (min) RT ratio USP resolution* 
PGR-II 5.51 0.35 - 
PIO-II 12.17 0.76 23.58 
Pioglitazone 15.98 1.00 10.91 
N-oxide 32.99 2.07 53.53 
RT: Retention time; USP: United states pharmacopoeia; *USP resolution between any peaks should be more than 1.5. 
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System precision 
The precision of an analytical procedure: expresses the nearness 
of treaty amongst a sequence of quantities obtained from 
multiple sampling of the same homogeneous sample under the 
prescribed conditions [26]. The standard solution was 
repeatedly injected and performed the calculation of % RSD for 
each peak. %RSD was obtained was less than 0.6% (limit: %RSD 
should be less than 4%). The system precision results have been 
given in table 3. 
  
Table 3: System precision results of PGR-II, PIO-II, N-oxide and pioglitazone 
Injection no. Area observed 
PGR-II PIO-II N-oxide Pioglitazone 
1 70906 40674 58335 38210 
2 71177 40876 58328 38367 
3 71172 40853 58556 38487 
4 70910 40883 58194 38191 
5 70547 41004 58160 38428 
6 70587 40946 58018 38168 
7 70481 40801 58157 38333 
8 70493 41295 58075 38748 
9 70536 40588 57914 38697 
10 70433 41054 58010 38413 
Mean 70724 40897 58175 38289 
SD 289.8593 198.2984 190.0509 199.1207 
%RSD* 0.41 0.48 0.33 0.52 
SD: Standard deviation; RSD: Relative standard deviation; * %RSD limit for 10 injections were should be less than 4% 
 
Method precision 
The precision of an analytical procedure: expresses the nearness 
of treaty amongst a series of quantities attained from several 
sampling of the identical homogeneous samples under the 
prescribed conditions [26]. The method precisions have been 
performed by six preparations of spiked sample solutions with 
impurities of PGR-II, PIO-II and N-oxide. The %RSD for the content 
of PGR-II, PIO-II and N-oxide was below 6% (limit: %RSD for 
content should be less than 10%). The %RSD for the content of 
impurities was within 6% in the intermediate precision which was 
performed by different analysts, column, instrument and day. The 
table 4 shows the results of method precision data. 
Limit of detection and limit of quantitation 
The limit of detection and limit of quantitation was examined based 
on signal-to-noise ratio method as per the ICH guideline Q2 (R1). 
The signal to noise ratio for a limit of detection is 3:1 and the limit of 
quantitation is 10:1. This was performed by performing the 
sequence of dilute solutions with a known concentration limit of 
detection and limit of quantification has been determined.  
The limit of detection for PGR-II, PIO-II, N-oxide and pioglitazone 
were 0.0007, 0.0020, 0.0018, and 0.0011% respectively. The limit of 
quantification for PGR-II, PIO-II, N-oxide and pioglitazone were 
0.0020, 0.0059, 0.0054, 0.0032 % respectively. 
 
Table 4: Method precision results of PGR-II, PIO-II and N-oxide 
Preparation no. % of PGR-II % of PIO-II % of N-oxide 
1 0.10 0.10 0.10 
2 0.10 0.09 0.10 
3 0.10 0.09 0.10 
4 0.10 0.10 0.10 
5 0.10 0.10 0.10 
6 0.10 0.10 0.10 
Mean 0.10 0.10 0.10 
%RSD* 0.0 5.2 0.0 
RSD: Relative standard deviation; *% RSD for content of impurities was should be less than 10% 
 
Table 5: Linearity data of PGR-II 
Sample No. % Level Concentration (µg/ml) Peak response 
1 LOQ 0.00041 1653 
2 30 0.000616 22562 
3 50 0.001026 37490 
4 100 0.002052 75191 
5 120 0.002462 80592 
6 200 0.004104 151625 
7 250 0.005130 185604 
Slope 36295198.1479 
Y-intercept -764.8861 
Multiple R 0.9985 
R square 0.9971 
LOQ: limit of quantitation 
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Linearity  
The linearity of the analytical procedure: is its capability to attain 
assessment outcomes which are straightly proportional to the 
concentration of an analyte in the sample [26]. Linearity was 
performed from LOQ to 250% of 2000 µg/ml analyte concentration. 
The correlation coefficient values have been shown in the table 5-8. 
The linearity graphs were shown in fig. 3-6. The values of multiple R 
and R-square were almost equal to one; this indicates that the 
developed method was linear. The regression results indicate that the 
validated method was linear over the total concentration and it was 
satisfactory for its concentration range from LOQ to 250%. The R-
square and multiple R values indicate that the method was linear and 
it was very close to the origin or close to the ideal theoretical value. 
 
Table 6: Linearity data of PIO-II 
Sample No. % level Concentration (µg/ml) Peak response 
1 LOQ 0.000118 2563 
2 30 0.000600 13031 
3 50 0.001000 21339 
4 100 0.002000 43834 
5 120 0.002400 51729 
6 200 0.004000 86483 
7 250 0.005000 105319 
Slope 21218800.9574 
Y-intercept 501.7382 
Multiple R 0.9998 
R square 0.9995 
 LOQ: limit of quantitation 
 
Table 7: Linearity data of N-oxide 
Sample No. % level Concentration (µg/ml) Peak response 
1 LOQ 0.000064 2388 
2 30 0.000597 20226 
3 50 0.000996 33079 
4 100 0.001992 68478 
5 120 0.002390 80713 
6 200 0.003983 134433 
7 250 0.004979 165330 
Slope 33349222.1603 
Y-intercept 625.0455 
Multiple R 0.9999 
R square 0.9997 
 LOQ: limit of quantitation 
 
Table 8: Linearity data of pioglitazone 
Sample No. % Level Concentration (µg/ml) Peak response 
1 LOQ 0.000109 2362 
2 30 0.000605 14950 
3 50 0.001008 23884 
4 100 0.002016 49743 
5 120 0.002420 57282 
6 200 0.004033 96295 
7 250 0.005041 119350 
Slope 23707392.2216 
Y-intercept 393.5717 
Multiple R 0.9998 
R square 0.9997 
 LOQ: limit of quantitation 
 
 
Fig. 3: Linearity graph for PGR-II 
 
Fig. 4: Linearity graph for PIO-II 
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Fig. 5: Linearity graph for N-oxide 
 
Regression 
The regression parameters of PGR-II, PIO-II, N-oxide and pioglitazone 
have been summarized in table 9. This explains about the statistical 
evaluation of ANOVA, confidence intervals and intercepts value with 
respect to 100% standard concentration response. 
 
Fig. 6: Linearity graph for pioglitazone 
 
Range 
PGR-II, PIO-II, N-oxide and pioglitazone were established in the 
range of 2.0-256.5%, 5.9-250.0%, 3.2-250.2% and 5.5-252.1% 
respectively.
Table 9: Regression statistics 
PGR-II ANOVA 
Degree of freedom (df) Sum of squares (SS) 
Regression  1 27465435079.1892 
Residual 5 80876504.2393 
Total 6 27546311583.4286 
PGR-II Confidence Intervals 
Lower 95% Upper 95% 
Intercept -7103.8007 5574.0285 
X Variable 1 34031004.6031 38559391.6926 
PIO-II ANOVA 
Degree of freedom (df) Sum of squares (SS) 
Regression  1 8772141115.7928 
Residual 5 4127381.6358 
Total 6 8776268497.4286 
PIO-II Confidence Intervals 
Lower 95% Upper 95% 
Intercept -942.2478 1945.7241 
X Variable 1 20689683.8784 21747918.0363 
N-oxide ANOVA 
Degree of freedom (df) Sum of squares (SS) 
Regression  1 21732116399.7025 
Residual 5 5734902.0117 
Total 6 21737851301.7143 
N-oxide Confidence Intervals 
Lower 95% Upper 95% 
Intercept -1067.2941 2317.3851 
X Variable 1 32726428.5752 33972015.7453 
Pioglitazone ANOVA 
Degree of freedom (df) Sum of squares (SS) 
Regression  1 11154571681.1543 
Residual 5 3631851.7028 
Total 6 11158203532.8571 
Pioglitazone Confidence Intervals 
Lower 95% Upper 95% 
Intercept -959.5021 1746.6455 
X Variable 1 23215615.6658 24199168.7775 
 ANOVA: Analysis of variance; Regression data shows that the validated method was statistically proven. 
 
Accuracy  
The accuracy of an analytical procedure: expresses the nearness of 
treaty amongst the value which is accepted either as a conventional 
factual value or a recognized reference value and the significance 
found. For the quantitative approaches, at least nine determinations 
across the specified range should be obtained [26]. The accuracy 
percentage for PGR-II, PIO-II and N-oxide were 98-105% for drug 
substance from LOQ to 250.0% level. This result indicates that the 
method was accurate and appropriate as the mean accuracy value was 
within the limit (80-120%).  
Specificity 
Specificity is the capability to judge the compound of interest 
unequivocally in the presence of components, which may be 
anticipated to be existent. Typically, these might include impurities, 
degradants, matrix, etc. [26]. Specificity of the method was 
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demonstrated by the peak purity, (i.e. the purity angle is lesser than 
the purity threshold) by way of the diode array detector for 
degraded samples. The specificity of the method was established 
with the pioglitazone in the existence of related impurities namely 
PGR-II, PIO-II and N-oxide. To prove the specificity; all forced 
degraded studied samples were performed at a test concentration of 
2000 µg/ml. The peak purity analysis was homogenous for PGR-II, 
PIO-II and N-oxide. There was no interference observed from blank 
peaks and impurities. There was no secondary peak aroused from 
degraded samples. The results of forced degradation study indicate 
that the method was stability indicating. The impurity PGR-II and 
PIO-II were process related impurities and N-oxide was degradation 
impurity. 
Robustness 
By careful variation in chromatographic conditions, the resolution 
between PGR-II, PIO-II, N-oxide and pioglitazone were evaluated. 
The mobile phase flow rate was 1.0 ml/min. To check the effect of 
flow rate on the resolution, 0.1 units changed it from 0.9 to 1.1 
ml/min. The column oven temperature was 45 °C. To check the 
effect of temperature on the resolution, 5 units changed it from 40 
°C to 50 °C. The % of mobile phase-A composition was 80%. To 
check the effect of mobile phase composition on the resolution, 2% 
units changed it from 78% to 82%. The % of mobile phase-B 
composition was 20%. To check the effect of mobile phase 
composition on the resolution, 2% units changed it from 18% to 
22%. The resolution between impurities and pioglitazone was 
greater than 5 in all the varied chromatographic conditions carried 
out (flow rate, the addition of trifluoroacetic acid and column 
temperature). The result shows that the method was considered 
robust. 
Solution stability 
The solution stability of pioglitazone and its impurities was 
carried out by freshly prepared standard and sample solution in a 
tightly closed volumetric flask at the room temperature (22-27 °C) 
as well as in the refrigerator at 2-8 °C for initial, 24 and 48 h. The 
result of solution stability shows that the solution was stable up to 
48 h at room temperature (22-27 °C) and also at 2-8 °C in the 
refrigerator. 
DISCUSSION 
The USP resolution between PIO-II and pioglitazone was 15.9 
which were 5 times more than that the obtained value of the 
research article [27]. The system precision results were very 
well within the acceptance criteria, i.e., %RSD for PIO-II, PGR-II, 
N-oxide and pioglitazone were observed within 0.5%. The %RSD 
value was obtained by the research work [27] was above 0.5% 
when compared to the present research study which was 
observed less than 0.5%. Moreover, the %RSD obtained in the 
validation was very less when compared to the previously 
published articles. The limit of detection and limit of 
quantitation results indicated that the method was sensitive to 
determine the content PGR-II, PIO-II and N-oxide in the sample 
of pioglitazone drug substance.  
The method precision results show that the developed method 
was very precise with the addition of impurities in the presence of 
pioglitazone hydrochloride when compared to the previously 
established works. The detection and quantitation limits of PIO-II, 
PGR-II, N-oxide and pioglitazone were observed low when 
compared to the previously published article [27] though the 
study was performed for several impurities. The developed 
method was linear from very low level to high level when 
compared to the previously published article [27]. The accuracy of 
the method has been demonstrated by the presence of impurities 
in pioglitazone hydrochloride at the specified levels with respect 
to the test concentration; the results show that the method was 
very accurate at the LOQ level itself. The specificity, solution 
stability and robustness of the method show that the impurity 
PGR-II and PIO-II were process related impurities and N-oxide was 
degradation impurity. This indicates that the equipment was 
suitable, accurate, precise, sensitive and fit for study. 
CONCLUSION 
The developed RP-HPLC method was developed and validated as per 
ICH guidelines in terms of system suitability, system precision, 
method precision, specificity/stress studies, accuracy, linearity, 
robustness, solution stability, limit of detection and limit of 
quantitation for the quantitative estimation of related substances of 
pioglitazone hydrochloride drug substance. The correlation 
coefficients were greater than 0.99. The precision results were good 
enough to say that the method developed is precise and 
reproducible. Accuracy studies revealed that mean recoveries after 
spiking experiments were between 98 and 105%, indicative of 
accurate method. Degradation studies reveal that the developed 
method was stability indicating hence, this method can easily and 
conveniently adopt for routine quality control analysis of the 
determination of related substances of pioglitazone drug substances 
in quality control laboratories. 
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